Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1985 Jul;82(13):4521–4525. doi: 10.1073/pnas.82.13.4521

Beta 2-adrenergic receptors contribute to catecholamine-stimulated shortening of action potential duration in dog atrial muscle.

B T Liang, L H Frame, P B Molinoff
PMCID: PMC391134  PMID: 2989829

Abstract

beta 1- and beta 2-adrenergic receptors coexist in atria of humans and a variety of other species. The significance of these receptors and the quantitative extent to which beta 2-adrenergic receptors contribute to the electrophysiologic effects of catecholamines acting at beta-adrenergic receptors have not been determined. In the present study, the beta 1-selective antagonist ICI 89,406 and the beta 2-selective antagonist ICI 118,551 were used to determine the relative densities of beta 1- and beta 2-adrenergic receptors on membranes prepared from dog atria and the contribution that each subtype makes to isoproterenol-induced shortening of action potential duration measured at 75% repolarization (APD75). Computer-aided nonlinear regression analysis of the inhibition of the specific binding of [125I]iodopindolol and the inhibition of isoproterenol-stimulated APD75 shortening by these antagonists showed that a two-site model fits the data better than a one-site model (P less than 0.0001). The affinity constants for each selective antagonist determined by inhibition of APD75 shortening were similar to those determined in studies of the inhibition of the specific binding of [125I]iodopindolol to beta 1- and beta 2-adrenergic receptors. beta 2-Adrenergic receptors made up approximately equal to 25% of the total number of beta-adrenergic receptors but mediated approximately equal to 50% of the electrophysiologic effect of isoproterenol. The inhibition of the binding of [125I]iodopindolol and of the APD75 shortening by propranolol, a nonselective antagonist, was best fit by a one-site model. In other experiments, dogs were treated with reserpine and atropine to eliminate complications caused by the presence of endogenous norepinephrine and acetylcholine. Results obtained with atria from these animals were similar to those obtained in studies with control atria. These data suggest that beta 2-adrenergic receptors as well as beta 1-adrenergic receptors are involved in mediating the electrophysiologic effects of catecholamines in dog atrial muscle and that both beta 1- and beta 2-adrenergic receptors are present on atrial muscle cells.

Full text

PDF
4521

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aurbach G. D., Fedak S. A., Woodard C. J., Palmer J. S., Hauser D., Troxler F. Beta-adrenergic receptor: stereospecific interaction of iodinated beta-blocking agent with high affinity site. Science. 1974 Dec 27;186(4170):1223–1224. doi: 10.1126/science.186.4170.1223. [DOI] [PubMed] [Google Scholar]
  2. Brodde O. E., Leifert F. J., Krehl H. J. Coexistence of beta 1- and beta 2-adrenoceptors in the rabbit heart: quantitative analysis of the regional distribution by (-)-3H-dihydroalprenolol binding. J Cardiovasc Pharmacol. 1982 Jan-Feb;4(1):34–43. doi: 10.1097/00005344-198201000-00007. [DOI] [PubMed] [Google Scholar]
  3. Carlsson E., Dahlöf C. G., Hedberg A., Persson H., Tångstrand B. Differentiation of cardiac chronotropic and inotropic effects of beta-adrenoceptor agonists. Naunyn Schmiedebergs Arch Pharmacol. 1977 Nov;300(2):101–105. doi: 10.1007/BF00505039. [DOI] [PubMed] [Google Scholar]
  4. Cheng Y., Prusoff W. H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973 Dec 1;22(23):3099–3108. doi: 10.1016/0006-2952(73)90196-2. [DOI] [PubMed] [Google Scholar]
  5. Harden T. K., Wolfe B. B., Molinoff P. B. Binding of iodinated beta adrenergic antagonists to proteins derived from rat heart. Mol Pharmacol. 1976 Jan;12(1):1–15. [PubMed] [Google Scholar]
  6. Hedberg A., Minneman K. P., Molinoff P. B. Differential distribution of beta-1 and beta-2 adrenergic receptors in cat and guinea-pig heart. J Pharmacol Exp Ther. 1980 Mar;212(3):503–508. [PubMed] [Google Scholar]
  7. Langer S. Z. Presynaptic regulation of the release of catecholamines. Pharmacol Rev. 1980 Dec;32(4):337–362. [PubMed] [Google Scholar]
  8. Lau Y. H., Robinson R. B., Rosen M. R., Bilezikian J. P. Subclassification of beta-adrenergic receptors in cultured rat cardiac myoblasts and fibroblasts. Circ Res. 1980 Jul;47(1):41–48. doi: 10.1161/01.res.47.1.41. [DOI] [PubMed] [Google Scholar]
  9. Maguire M. E., Wiklund R. A., Anderson H. J., Gilman A. G. Binding of (125I)iodohydroxybenzylpindolol to putative beta-adrenergic receptors of rat glioma cells and other cell clones. J Biol Chem. 1976 Mar 10;251(5):1221–1231. [PubMed] [Google Scholar]
  10. McGonigle P., Huff R. M., Molinoff P. B. A comprehensive method for the quantitative determination of dopamine receptor subtypes. Ann N Y Acad Sci. 1984;430:77–90. doi: 10.1111/j.1749-6632.1984.tb14499.x. [DOI] [PubMed] [Google Scholar]
  11. Minneman K. P., Hegstrand L. R., Molinoff P. B. Simultaneous determination of beta-1 and beta-2-adrenergic receptors in tissues containing both receptor subtypes. Mol Pharmacol. 1979 Jul;16(1):34–46. [PubMed] [Google Scholar]
  12. Minneman K. P., Pittman R. N., Molinoff P. B. Beta-adrenergic receptor subtypes: properties, distribution, and regulation. Annu Rev Neurosci. 1981;4:419–461. doi: 10.1146/annurev.ne.04.030181.002223. [DOI] [PubMed] [Google Scholar]
  13. Refshauge C., Kissinger P. T., Dreiling R., Blank L., Freeman R., Adams R. N. New high performance liquid chromatographic analysis of brain catecholamines. Life Sci. 1974 Jan 16;14(2):311–322. doi: 10.1016/0024-3205(74)90061-7. [DOI] [PubMed] [Google Scholar]
  14. Robberecht P., Delhaye M., Taton G., De Neef P., Waelbroeck M., De Smet J. M., Leclerc J. L., Chatelain P., Christophe J. The human heart beta-adrenergic receptors. I. Heterogeneity of the binding sites: presence of 50% beta 1- and 50% beta 2-adrenergic receptors. Mol Pharmacol. 1983 Sep;24(2):169–173. [PubMed] [Google Scholar]
  15. Stiles G. L., Caron M. G., Lefkowitz R. J. Beta-adrenergic receptors: biochemical mechanisms of physiological regulation. Physiol Rev. 1984 Apr;64(2):661–743. doi: 10.1152/physrev.1984.64.2.661. [DOI] [PubMed] [Google Scholar]
  16. Wit A. L., Hoffman B. F., Rosen M. R. Electrophysiology and pharmacology of cardiac arrhythmias. IX. Cardiac electrophysiologic effects of beta adrenergic receptor stimulation and blockade. Part A. Am Heart J. 1975 Oct;90(4):521–533. doi: 10.1016/0002-8703(75)90436-6. [DOI] [PubMed] [Google Scholar]
  17. Yabuuchi Y., Yamashita S., Tei S. S. Pharmacological studies of OPC-2009, a newly synthesized selective beta adrenoceptor stimulant, in the broncho-motor and cardiovascular system of the anesthetized dog. J Pharmacol Exp Ther. 1977 Aug;202(2):326–336. [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES